Nephrology and Urology Devices Market Size & Growth Forecast 2026–2035, By Segments (End-use, Application, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Nephrology and Urology Devices Market size was worth USD 6.7 Billion in 2025 and is expected to grow at a 7% CAGR between 2026 and 2035, surpassing USD 13.18 Billion by 2035. The industry revenue for 2026 is assessed at USD 7.11 billion.

• Base Year Value (2025): USD 6.7 Billion
• CAGR (2026-2035): 7%
• Forecast Year Value (2035): USD 13.18 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Nephrology and Urology Devices Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America holds a 34.87% share, supported by strong procedure volumes, established care pathways, and widespread use of dialysis, catheter, and endoscopic devices across healthcare facilities.
  • Asia Pacific is projected to grow at 7.91% CAGR due to expanding healthcare infrastructure, improved diagnostic access, and rising demand for dialysis and interventional renal and urological treatments.

• Segment Momentum:

  • Hospitals held a 44.5% share in 2025 because they manage complex renal and urological conditions using advanced infrastructure, multidisciplinary care, and comprehensive diagnostic and interventional device capabilities.
  • Kidney Diseases are the fastest-growing application as demand shifts toward long-term renal care, increasing the need for devices supporting patient monitoring, therapy delivery, and access management.

• Market Expansion Drivers:

  • Rising chronic kidney disease and urolithiasis prevalence increasing long-term demand for renal intervention devices.
  • Growing adoption of minimally invasive endourological procedures accelerating specialized catheter and stent utilization.
  • Expanding outpatient urology infrastructure strengthening demand for portable and disposable treatment devices.

• Leading Market Participants:

  Leading companies in the nephrology and urology devices market include Boston Scientific Corporation (United States), Baxter International Inc. (United States), Fresenius Medical Care AG (Germany), Becton, Dickinson and Company (United States), Coloplast A/S (Denmark), B. Braun SE (Germany), Teleflex Incorporated (United States), Olympus Corporation (Japan), Terumo Corporation (Japan), Cook Medical LLC (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 6.7 Billion
  • Projected Market Size: USD 13.18 Billion by 2035
  • Growth Forecasts: 7% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Hospitals (End-use) | Urolithiasis (Application) | Ureteral Catheters (Product)
  • Emerging Opportunity Segment: Ambulatory Surgical Centers (End-use) | Kidney Diseases (Application) | PCN Catheters (Product)

Market Growth Drivers and Industry Trends

Rising chronic kidney disease and urolithiasis prevalence increasing long-term demand for renal intervention devices

A growing patient pool with chronic kidney disease and recurrent stone disease is steadily reshaping purchasing patterns in the nephrology and urology devices market, as care pathways increasingly require repeated monitoring, drainage, access, and intervention rather than one-time treatment. Chronic kidney disease creates sustained use of dialysis access devices, catheters, and related renal support equipment, while urolithiasis drives recurring demand for stents, guidewires, stone management tools, and post-procedure consumables because relapse and follow-up interventions are common. This clinical recurrence supports market expansion by making device utilization more continuous and predictable for hospitals, dialysis centers, and urology practices, which in turn influences inventory planning, supplier relationships, and procurement priorities in the nephrology and urology devices market.

Growing adoption of minimally invasive endourological procedures accelerating specialized catheter and stent utilization

As physicians and care providers shift toward endourological techniques that reduce recovery time, lower procedural trauma, and fit modern treatment preferences, the nephrology and urology devices market is seeing stronger pull-through demand for procedure-specific catheters, ureteral stents, access sheaths, and related disposable instruments. These interventions depend on precise navigation and temporary internal drainage, making specialized device performance central to procedural success rather than a secondary consideration. The result is increasing market penetration for higher-value consumables and replacement-driven product cycles, as providers standardize around devices that improve ease of placement, procedural efficiency, and postoperative management in the nephrology and urology devices market.

Expanding outpatient urology infrastructure strengthening demand for portable and disposable treatment devices

The gradual shift of suitable urology procedures into ambulatory surgery centers, office-based settings, and other outpatient facilities is changing the product mix in the nephrology and urology devices market toward devices that are easier to deploy outside large hospital environments. Portable systems, single-use instruments, and disposable treatment components fit these settings because they simplify sterilization workflows, reduce turnaround time between cases, and support efficient scheduling with limited on-site reprocessing capacity. This infrastructure expansion is contributing to market size growth by favoring device formats that align with faster patient throughput, lower procedural complexity, and decentralized service delivery in the nephrology and urology devices market.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising chronic kidney disease and urolithiasis prevalence increasing long-term demand for renal intervention devices	2.00%	Moderate	North America, Asia Pacific	High	Near Term
Growing adoption of minimally invasive endourological procedures accelerating specialized catheter and stent utilization	1.80%	Moderate	Europe, North America	High	Mid Term
Expanding outpatient urology infrastructure strengthening demand for portable and disposable treatment devices	1.40%	Low	Asia Pacific, Latin America	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 34.87% share of the nephrology and urology devices market in 2025, backed by established renal and urological care pathways, broad availability of advanced treatment devices, and strong procedure volumes across hospitals, ambulatory centers, and specialty clinics. The region’s leadership is reinforced by routine diagnosis and management of chronic kidney and urinary disorders, which sustains consistent demand for dialysis equipment, endoscopic systems, catheters, and related consumables. A mature provider network and higher integration of device-based interventions into standard clinical practice also help maintain steady purchasing and replacement activity.

Asia Pacific is projected to expand at a 7.91% CAGR over the forecast period in the nephrology and urology devices market, driven by rising access to specialized care, expanding hospital infrastructure, and growing adoption of modern renal and urological treatment technologies. Growth is accelerating as more patients enter the treated population through improving diagnostic access and broader availability of interventional and dialysis services across urban and developing healthcare markets. Demand is also being fueled by the practical need to scale treatment capacity, prompting providers to invest in device procurement as clinical volumes increase.

Key Country Insights

United States

Advanced Clinical Solutions

The U.S. continues to adopt advanced nephrology and urology devices that support minimally invasive procedures, dialysis efficiency, and improved patient management. Healthcare providers are investing in technologies that enhance clinical outcomes while supporting workflow optimization across specialized care settings.

Japan

Aging Care Support

Japan is expanding the use of nephrology and urology devices to address increasing demand for chronic kidney disease management and age-related urological care. Healthcare institutions are focusing on patient-friendly technologies that improve treatment efficiency and clinical reliability.

South Korea

Minimally Invasive Adoption

South Korea is increasing the adoption of nephrology and urology devices that support minimally invasive interventions and advanced diagnostic capabilities. Hospitals are integrating modern treatment systems to improve patient experience and streamline specialized clinical procedures.

Germany

Precision Treatment Technologies

Germany is emphasizing nephrology and urology devices that improve procedural precision and long-term patient care within hospital and specialty clinic environments. German healthcare providers are prioritizing durable equipment, digital integration, and consistent treatment performance.

France

Hospital Care Optimization

France is modernizing nephrology and urology services by incorporating devices that strengthen diagnostic accuracy, dialysis performance, and procedural efficiency. French healthcare providers are aligning equipment investments with evolving standards for specialized patient care.

Italy

Specialized Treatment Expansion

Italy is enhancing nephrology and urology care through broader adoption of specialized devices across hospitals and outpatient facilities. Italian healthcare organizations are focusing on technologies that improve procedural effectiveness, patient safety, and long-term disease management.

Segment Leadership and Growth Trends

  End-use Segment Analysis: Hospitals (Largest Segment) vs Ambulatory Surgical Centers (Fastest-Growing Segment)

Hospitals held a 44.5% share of the nephrology and urology devices market in 2025, reflecting their central role in managing complex renal and urological conditions that require advanced infrastructure, multidisciplinary care, and continuous patient monitoring. Their leadership is maintained through the concentration of high-acuity procedures, broad device availability across diagnostics and intervention, and the ability to handle complications or comorbidities that are less practical to manage in smaller care settings.

Ambulatory Surgical Centers are emerging as the fastest-growing end-use segment in the nephrology and urology devices market as procedure volumes increasingly shift toward efficient outpatient settings. Their momentum is supported by demand for less invasive urology interventions, faster patient turnaround, and a care delivery model that aligns well with procedures that do not require prolonged hospital stays. Compared with hospitals, these centers are gaining traction where cost control and workflow efficiency are shaping device adoption decisions.

Application Segment Analysis: Urolithiasis (Largest Segment) vs Kidney Diseases (Fastest-Growing Segment)

Within the nephrology and urology devices market, Urolithiasis accounted for the largest share in 2025, supported by the consistent need for procedural intervention and device use across diagnosis, stone management, and follow-up care. Its leading share is maintained by the routine clinical burden of stone disease, which often requires repeat imaging, endoscopic tools, and fragmentation or removal devices, creating steady and recurring demand across care settings.

Kidney Diseases represent the fastest-growing application segment in the nephrology and urology devices market as treatment demand expands beyond episodic intervention toward ongoing disease management. Growth is being influenced by the practical need for devices that support long-term renal care, where patient monitoring, access management, and therapy delivery create a broader and more sustained use profile than many procedure-focused applications.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
End-use	Hospitals, Clinics, Ambulatory Surgical Centers, Others	Hospitals	Ambulatory Surgical Centers
Application	Urolithiasis, Urological Cancer & BPH, Bladder Disorders, Kidney Diseases, Others	Urolithiasis	Kidney Diseases
Product	Ureteral Catheters, PCN Catheters, Urinary Stents, Stone Basket, Urology Guidewires, Renal Dilators, Others	Ureteral Catheters	PCN Catheters

Competitive Landscape and Market Positioning

Major players in the nephrology and urology devices market:

1. Boston Scientific Corporation (United States)

2. Baxter International Inc. (United States)

3. Fresenius Medical Care AG (Germany)

4. Becton Dickinson and Company (United States)

5. Coloplast A/S (Denmark)

6. B. Braun SE (Germany)

7. Teleflex Incorporated (United States)

8. Olympus Corporation (Japan)

9. Terumo Corporation (Japan)

10. Cook Medical LLC (United States)

The nephrology and urology devices market is advancing through improved diagnostic and treatment technologies. Device innovation is enhancing precision and patient outcomes. Continuous development efforts are supporting minimally invasive solutions. Expanding clinical applications are strengthening adoption across healthcare systems.

Industry Development/News

Company Name	Date	Key Development
Medline Industries, LP.	Jan-26	Medline Industries, LP. opened a new office in Riyadh, Saudi Arabia, to bolster its presence in the Middle East. The facility serves as a regional hub to improve service responsiveness and deepen customer engagement across the growing Saudi Arabian and regional healthcare markets.
ProVerum Limited	Dec-25	The U.S. FDA approved ProVerum’s ProVee System, a next-generation prostatic urethral stent for benign prostatic hyperplasia (BPH). The device offers a minimally invasive, "no-cut" solution for urinary obstruction, providing an improved safety profile and faster patient recovery times compared to traditional surgical interventions.
Fresenius Medical Care	Mar-25	Fresenius Medical Care expanded its bibag (dry bicarbonate concentrate) production at its Jaguariúna facility in São Paulo, Brazil. The investment introduced a highly automated production line, significantly increasing output capacity to meet both domestic Brazilian demand and export requirements across Latin America.